ClinicalTrials.gg
Not yet recruitingNCT07864233Updated Oct 7, 2026

ATR-FTIR and Raman Spectroscopy of Peri-Implant Crevicular Fluid in Peri-Implantitis

An observational study in Peri-Implantitis, sponsored by Necmettin Erbakan University. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Necmettin Erbakan University · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Peri-implantitis is an inflammatory condition affecting the tissues surrounding dental implants and may lead to supporting bone loss. Current diagnosis is mainly based on clinical and radiographic findings. However, these methods may not fully reflect the biological changes occurring around implants.

The purpose of this observational study is to evaluate whether peri-implant crevicular fluid (PICF), a biological fluid collected from around dental implants, shows different molecular characteristics in peri-implant health and peri-implantitis. Adults who have at least one healthy dental implant and one implant with peri-implantitis will be included.

For each participant, PICF samples will be collected from one healthy implant and one peri-implantitis implant. The samples will be analyzed using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and Raman spectroscopy. These techniques provide molecular information about biological samples without requiring additional invasive procedures.

The study will compare the spectral profiles obtained from healthy and peri-implantitis sites and evaluate whether these profiles can distinguish peri-implant health from peri-implantitis. Relationships between spectral findings and clinical factors, including probing depth, bleeding on probing, suppuration, radiographic bone loss, smoking status, and diabetes status, will also be explored.

Read the detailed description

This is an observational, analytical, cross-sectional clinical study with a within-participant split-mouth design. The study aims to characterize peri-implant crevicular fluid (PICF) obtained from peri-implant healthy and peri-implantitis sites using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and Raman spectroscopy.

Adults aged 18 years or older who have at least two dental implants, including at least one implant meeting the criteria for peri-implant health and at least one implant diagnosed with peri-implantitis, will be eligible for participation. Dental implants must have been in function for at least one year. Peri-implantitis will be diagnosed according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

For each participant, one peri-implant healthy implant and one peri-implantitis implant will be selected for evaluation. If more than one peri-implantitis implant is eligible, the implant with the greatest probing depth and radiographic bone loss will be selected. If clinical findings are similar, random selection will be used. When more than one healthy implant is available, preference will be given to an implant located in the same jaw as the peri-implantitis implant, with random selection used when necessary.

Clinical peri-implant parameters will include plaque index, bleeding on probing, probing depth, suppuration, keratinized mucosal width, and radiographic bone loss. Implant-related characteristics, including time in function and prosthetic retention type, will also be recorded. Participant-level information including age, sex, systemic disease history, smoking status, diabetes status, and body mass index will be collected.

PICF samples will be obtained after isolation of the sampling site and removal of supragingival plaque. Sterile PerioPaper strips will be inserted into the peri-implant sulcus for 30 seconds. Samples contaminated with blood or saliva will be excluded. Collected samples will be stored at -80°C until spectroscopic analysis.

ATR-FTIR spectroscopy will be used to evaluate molecular spectral features associated with proteins, lipids, carbohydrates, nucleic acids, and other biochemical components. Raman spectroscopy will provide complementary molecular information based on light-scattering characteristics. Technical replicate measurements will be performed to improve the reliability and representativeness of the spectral data.

Spectral data will undergo exploratory and classification analyses. Principal component analysis (PCA) will be used for exploratory evaluation, and classification approaches may include partial least squares discriminant analysis (PLS-DA), support vector machine (SVM), and Random Forest. Classification performance will be evaluated using receiver operating characteristic area under the curve (ROC-AUC), sensitivity, specificity, accuracy, and confusion matrices. Validation procedures will be performed at the participant level to reduce the risk of data leakage.

The primary objective is to determine the ability of ATR-FTIR and Raman spectral profiles of PICF to distinguish peri-implant health from peri-implantitis within the same participant. Secondary analyses will evaluate associations between spectral findings and clinical or systemic parameters, compare the diagnostic performance of ATR-FTIR and Raman spectroscopy, and assess the performance of machine-learning-based classification models. Smoking and diabetes status will also be evaluated as exploratory secondary variables when the available sample size permits.

02

Conditions studied

  • Peri-Implantitis

Browse trials for

Keywords

  • Peri-Implant Crevicular Fluid
  • PICF
  • Peri-Implant Health
  • ATR-FTIR Spectroscopy
  • Raman Spectroscopy
03

In context

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

This study's planned enrollment of 100 is above the median of 84 across 122 observational studies indexed under Peri-Implantitis.

Browse Peri-Implantitis studies →

Lead sponsor

Necmettin Erbakan University is the lead sponsor of 201 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older presenting to the Periodontology Clinic of Necmettin Erbakan University Faculty of Dentistry who have at least two dental implants, including at least one peri-implant healthy implant and at least one implant diagnosed with peri-implantitis. One healthy implant and one peri-implantitis implant from each eligible participant will be evaluated in a within-participant split-mouth design.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older Presence of dental implants that have been in function for at least 1 year Presence of at least one peri-implant healthy implant and at least one implant with peri-implantitis in the same participant Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding Use of systemic antibiotics within the previous 3 months History of periodontal or peri-implant treatment within the previous 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants With Paired Peri-Implant Sites

    Participants with at least one peri-implant healthy implant and at least one implant diagnosed with peri-implantitis. One healthy implant and one peri-implantitis implant from each participant will be evaluated and compared using a within-participant split-mouth design.

    Other: ATR-FTIR and Raman Spectroscopic Analysis of Peri-Implant Crevicular Fluid

Interventions

  • OtherATR-FTIR and Raman Spectroscopic Analysis of Peri-Implant Crevicular Fluid

    Peri-implant crevicular fluid (PICF) samples will be collected from one peri-implant healthy implant and one peri-implantitis implant in each participant using sterile PerioPaper strips. The samples will be analyzed using ATR-FTIR and Raman spectroscopy to characterize molecular spectral profiles and compare peri-implant health with peri-implantitis.

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance of Raman Spectral Profiles

    The ability of peri-implant crevicular fluid (PICF) spectral profiles obtained by Raman spectroscopy to discriminate between peri-implant health and peri-implantitis will be evaluated using receiver operating characteristic analysis. Diagnostic performance will be reported using the area under the receiver operating characteristic curve (AUC).

    Time frame: Baseline

  2. Diagnostic Performance of ATR-FTIR Spectral Profiles

    The ability of peri-implant crevicular fluid (PICF) spectral profiles obtained by ATR-FTIR spectroscopy to discriminate between peri-implant health and peri-implantitis will be evaluated using receiver operating characteristic analysis. Diagnostic performance will be reported using the area under the receiver operating characteristic curve (AUC).

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Oct 7, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864233
Responsible party
Osman Babayigit (Associate Professor, Necmettin Erbakan University) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Osman Babayiğit
Contact
obabayigit@erbakan.edu.tr
+905063208474

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion